Table 5

Demographic features of patients with two or more liver biopsies

No treatment between biopsies 1 and 2Treated between biopsies 1 and 2p Value
Values are mean (SD) or number (%).
IVDU, intravenous drug use.
2 test
†Independent t test.
No of patients (%)
    Male58 (62.4)26 (57.8)
    Female35 (37.6)19 (42.2)0.33*
Age at infection25.8 (10.3)29.8 (11.6)0.112†
Age at biopsy43.1 (10.84)45.55 (9.83)0.218†
Necroinflammatory score (Ishak) bx13.04 (1.92)4.09 (1.76)0.003†
Fibrosis score bx1
    Ishak1.94 (1.82)2.89 (1.86)0.005†
    METAVIR1.24 (1.27)1.86 (1.4)0.02†
Duration infection to 1st biopsy (y)15.6 (7.3)16.9 (8.19)0.464†
Duration 1st biopsy to 2nd biopsy2.73 (1.38)2.67 (1.24)0.801†
Rate infection to 1st biopsy (fibrosis units/y)
    Ishak0.150.22 (0.23)0.177†
    METAVIR0.0960.12 (0.16)0.218†
Risk factors (%)
    Blood19 (20.4)14 (31.1)
    IVDU29 (31.2)18 (40)0.133*
    Unknown45 (48.4)13 (28.9)
Alcohol consumption (units/week) (%)
    Unknown35 (37.6)17 (37.8)
    <4046 (49.6)17 (37.8)0.189*
    >4012 (12.9)11 (24.4)
Caucasian70 (75.3)34 (75.6)0.971*
Non-Caucasian23 (24.7)11 (24.4)
Viral genotype (%)
    125 (26.9)12 (26.7)
    Non-116 (17.2)10 (22.2)0.765*
    Unknown52 (55.9)23 (51.1)